Final MRI Results at 6 Months from a Phase 2 Multicenter Study of Ublituximab, A Novel Glyocoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS), Demonstrates Complete Elimination of Gd-Enhancing Lesions

Download

Drug Category : Array

Conference Category : Array

Lead Author : Inglese M, et al.

Published Date : 24/04/2018

Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2019/03/Final-2018-AAN-TGTX-Poster.pdf

Download Text : Download

Popup Confirmation? :

site-sidebar-layout : default

ast-site-content-layout : default

site-content-style : default

site-sidebar-style : default

theme-transparent-header-meta : default

stick-header-meta : default

astra-migrate-meta-layouts : set